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Combined Intraarterial/Intravenous Thrombolysis for
Acute Ischemic Stroke
Valdis Keris, Svetlana Rudnicka, Vladimirs Vorona, Gertrude Enina, Biruta Tilgale, and Juris Fricbergs
BACKGROUND AND PURPOSE: The intravenous use of recombinant tissue-type plasmin-
ogen activator (rTPA) in acute ischemic stroke has been investigated in three large trials.
Limited series have reflected outcome after local intraarterial thrombolysis (LIT) in the cere-
bral territory. The purpose of this study was to evaluate the safety and efficacy of combined
intraarterial/intravenous thrombolysis using rTPA (actilyse) for acute ischemic stroke.
METHODS: Forty-five patients with acute onset of severe hemispheric stroke and without
signs of major cerebral infarction on early CT scans were randomized by order of admission.
Twelve patients were treated with 50 mg actilyse (maximal dose, 0.7 mg/kg); three had occlu-
sion of the internal carotid artery and nine had occlusion of the middle cerebral artery. Throm-
bolysis was started by LIT and continued intravenously within 6 hours of stroke onset. Out-
come, assessed after 1 and 12 months according to the modified Rankin scale (MRS), was
considered good (MRS score, 0–3) for patients who were functionally independent and poor
(MRS score, 4–5) for those who were dependent or had died.
RESULTS: In the thrombolysis group, outcome was good in eight patients at 1 month and
in 10 patients at 12 months; in the control group, outcome was good in seven (21%) and 11
(33%) patients, respectively. Of the eight patients with a good outcome after thrombolysis, four
had complete and one had partial recanalization. In the control group, the rate of intracerebral
hemorrhage was 6%. Mortality at 1 month in the thrombolysis and control groups was 17%
and 48%, respectively.
CONCLUSIONS: Combined intraarterial/intravenous thrombolysis with low-dose rTPA may
be a safe and effective treatment for acute ischemic stroke within 6 hours in carefully selected
patients.
One of the main objectives in the treatment of acute
cerebral ischemia is the rapid restoration or im-
provement of blood flow in an affected vascular
territory. Recombinant tissue-type plasminogen ac-
tivator (rTPA) has been recognized as a promising
agent because of its endogenous origin, short half-
life in plasma, and high fibrin specificity, all of
which promise to promote encouraging clinical re-
sults. However, the results of three large, random-
ized, placebo-controlled trials of thrombolytic ther-
apy with intravenous rTPA have not been
unequivocal (1–3). Some authors have reported a
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good outcome after local intraarterial thrombolysis
(LIT) with different thrombolytic drugs (4–7) and
others have described LIT followed by percutane-
ous transluminal angioplasty or carotid endarter-
ectomy (8) or another intracranial manipulation (9)
in limited series of stroke patients. The combined
reported experience indicates that there are still at
least three issues to be addressed before adminis-
tration of rTPA becomes routine in patients with
acute stroke: inclusion criteria, technical approach,
and dose range. The purpose of this open-label
study was to assess the safety and efficacy of com-
bined intraarterial/intravenous administration of
low-dose rTPA in patients with acute ischemic
stroke.
Methods
During the period from February 1997 to March 1998, 612
patients with acute ischemic stroke were treated at our hospital,
of whom 219 were admitted within 6 hours after onset of
symptoms. All these patients underwent unenhanced CT stud-
ies, which were assessed by a neuroradiologist. If early CT
scans showed such changes as sulcal effacement, mass effect,
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edema, or possible hemorrhage, the patient was excluded from
the study, in accordance with reported guidelines (10).
Corresponding to a study protocol approved by an institu-
tional review committee, LIT was considered a possible treat-
ment if it could be completed within 6 hours of stroke (5) and
if the patient was not over 80 years old (11). To ensure a better
match between treated patients and control subjects, only pa-
tients with symptoms referable to the internal carotid artery
(ICA) territory were included. Exclusion criteria for throm-
bolysis were adopted from the National Institute of Neurolog-
ical Disorders and Stroke (NINDS) study (1). Pretreatment ex-
amination revealed 45 eligible patients who presented with a
severe but stable hemispheric syndrome who were then ran-
domized to either the thrombolysis or control group, one after
another, according to the order of admission. After informed
consent requirements were completed, only 12 patients re-
mained in the thrombolysis group whereas 33 patients were
included in the conventional treatment, or control, group. Base-
line characteristics of the patients in the two groups appear in
Table 1. All patients had a score of 20 or higher on the Na-
tional Institutes of Health Stroke Scale (NIHSS) (12) at the
onset of treatment.
The patients in the control group were transferred directly
to the intensive care unit (ICU), while those in the thrombol-
ysis group underwent cerebral angiography. Inclusion criteria
for angiography required complete occlusion of the ICA or the
middle cerebral artery (MCA) trunk (M1) or branch (M2) in
the appropriate carotid territory, consistent with the patient’s
clinical presentation (13, 14). Among the 12 consecutive pa-
tients enrolled in the thrombolysis group, three had occlusion
of the ICA and nine had occlusion of the MCA.
For the infusion, 50 mg of actilyse (Boehringer Ingelheim
Pharma GmbH, Gaithersburg, MD) was dissolved in 50 mL of
sterile water (dose rate, 0.57–0.70 mg/kg). Intraarterial injec-
tion of a 25-mg dose was performed manually over a period
of 5 to 10 minutes and was located selectively depending on
the site of arterial occlusion. If the MCA was thrombosed, a
catheter was placed into the M1 origin. If the ICA was oc-
cluded extracranially, actilyse was injected into the arterial
stump. There were no attempts to insert the catheter into the
thrombus, and the catheter position was not changed during
the injection. When the injection was completed, the patient
was transferred to the ICU, where the remainder of the dose
of actilyse (25 mg) was injected intravenously via an infusion
pump over a period of 60 minutes. A femoral introducer was
left in place until the following day, when CT and angiography
were performed again.
All the patients included in the study received standard neu-
rovascular care, including heparin at an initial dose of 5000 U
and thereafter at 5000 U twice a day for several days, after
which the patient was maintained on either aspirin or warfarin.
If hemorrhagic conversion occurred, heparin was discontinued.
Evaluation of anatomic results and clinical outcome was
based on findings on repeat CT studies, control angiograms,
and neurologic examination performed during the first 24
hours, at the time of discharge from the hospital, at 1 month,
and again at 12 months. Early neurologic improvement was
classified as significant if the patient improved by four or more
points on the NIHSS at 24 hours (11), although this was not
recognized as the end point of the study. Arterial patency was
rated by the thrombolysis in myocardial infarction classifica-
tion scheme (15), in which 0 indicates no perfusion, 1 is pen-
etration beyond obstruction but no perfusion of distal beds, 2
is incomplete recanalization with slower distal perfusion, and
3 is full perfusion.
Outcome was assessed according to the modified Rankin
scale (MRS), which is a handicap scale (16) on which patients
are graded with reference to their previous lifestyle from 0
(absence of symptoms) to 6 (death). Outcome was grouped
into two categories: good (MRS score, 0–3) for those patients
who were functionally independent, or poor for those who
were dependent (MRS score, 4–5) or had died.
Results
The protocol of thrombolysis was successfully
completed in all patients without any side effects.
Follow-up CT studies revealed hemorrhagic con-
version in two patients (17%). In both cases, the
hemorrhage was located in the core of the infarc-
tion with a diameter of less than 2 cm and was not
associated with neurologic deterioration. Two other
patients died within 4 days of progressive stroke
and fatal swelling of the hemisphere, despite partial
recanalization of an occluded artery in one of the
patients. Comparison of baseline characteristics,
anatomic results of thrombolysis, and outcome at 1
month (Table 2) showed that clinical improvement
was not always associated with reopening of the
occluded artery. However, complete recanalization
was achieved in all M2 occlusions.
In the control group, hemorrhagic conversion oc-
curred in two patients (6%) and one of them died.
Within 1 month, 16 (48%) of the patients in the
control group died (overall mortality for those ad-
mitted within 6 hours after stroke was 30%) and
10 remained functionally dependent. This made the
outcome at 1 month poor for 26 (79%) of the pa-
tients in this group. An additional analysis of out-
come by subgroups was performed among the con-
trol subjects for possible impact of age and location
of stroke. The mean age in the good (n 5 7), poor-
disabled (n 5 10), and poor-dead (n 5 16) sub-
groups was 65 6 9.7, 65 6 5.9, and 65 6 8.8
years, respectively. Therefore, the mean age across
subgroups was regarded as similar. The rate of
stroke in the left ICA territory for those who sur-
vived was 57% (four patients) in the good sub-
group and 50% (five patients) in the poor-disabled
subgroup.
Comparison of outcomes in the study subgroups
is presented in Table 3. Although the rate of hem-
orrhagic conversion in the thrombolysis group
(17%) was much higher than that in the control
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TABLE 2: Comparison of baseline characteristics, anatomic results of thrombolysis, and outcome at 1 month
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Note.—LIT indicates local intraarterial thrombolysis; NIHSS, National Institutes of Health Stroke Scale; AF, atrial fibrillation; (H), hemorrhage
on CT; ICA, internal carotid artery.
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FIG 1. Case 4.
A and B, Frontal projection shows occlu-
sion of left M1 trunk before thrombolysis
(arrow, A) and partial recanalization of ar-
tery with remnant of thrombus on control
angiogram (arrows, B).
group (6%), an adverse association between throm-
bolysis and poor outcome was observed. At 12
months, 83% of the patients in the thrombolysis
group were functionally independent whereas only
33% of the control subjects had a good outcome.
Representative Cases
Case 4.—A 77-year-old man presented with sud-
den onset of right hemiplegia and global aphasia.
He was not alert but arousable, and his baseline
NIHSS score was 26. A CT scan on admission re-
vealed no abnormalities. Angiography confirmed
complete occlusion of the left MCA trunk (Fig 1A).
LIT was initiated 3 hours 15 minutes after the onset
of symptoms. Control angiography performed the
next day revealed partial recanalization of the left
M1 trunk with residual thrombus (Fig 1B) and
slower distal perfusion. A follow-up CT study
showed no cerebral edema; however, there was a
low-density area in the territory of the left MCA.
At 24 hours, positive neurologic changes occurred,
with severe paresis in the arm and moderate paresis
in the leg (NIHSS score, 23). After 1 month, there
was moderate paresis in the arm, mild paresis in
the leg, and moderate aphasia (MRS score, 3). Mo-
tor function and language skills were better (MRS
score, 2) at the final follow-up at 12 months.
Case 9.—A 48-year-old man presented with a
severe left hemiparesis, left homonymous hemian-
opia, and drowsiness. Results of an initial CT scan
were normal. Angiography showed distal occlusion
of the right MCA parietooccipital branch (Fig 2A).
LIT was started 4 hours after the onset of stroke.
A control angiogram revealed recanalization of the
right M2 branch (Fig 2B), and a CT scan the next
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FIG 2. Case 9.
A and B, Lateral projection shows distal
occlusion of M2 branch before thromboly-
sis (arrow, A) and complete recanalization
on control angiogram (arrow, B).
day showed a low-density area with a high-density
core in the right MCA territory. At 24 hours, the
patient’s neurologic status had improved signifi-
cantly, to minor left hemiparesis and partial hemi-
anopia. An MR examination after 2 weeks showed
three small infarctions in the territory of the former
low-density area detected by CT: one (frontotem-
poral) with a trace of hemorrhage and two (parietal
and parasagittal) without hemorrhage. The patient
recovered well, and after 12 months there was no
evidence of disability (MRS score, 0).
Discussion
Since the first report on thrombolysis in the treat-
ment of cerebral artery occlusion (17), early throm-
bolytic intervention in patients with acute ischemic
stroke has been a continuing challenge. The most
thoroughly studied thrombolytics are streptokinase
and rTPA, followed by urokinase and pro-uroki-
nase. Because three trials of streptokinase were
stopped because of high rates of acute mortality
and intracranial bleeding (18–20), clinical interest
is presently focused on rTPA (21).
When administrated within 90 minutes of symp-
tom onset, intravenous rTPA at doses of less than
0.95 mg/kg have proved relatively safe with regard
to hemorrhagic complications (22). In the NINDS
study (1), intravenous rTPA in a dose of 0.9 mg/
kg (maximum, 90 mg) within 3 hours improved
clinical outcome at 3 months despite an increased
rate of symptomatic intracerebral hemorrhage, and
in the European Cooperative Acute Stroke Study
(ECASS II), treatment with the same dose within
6 hours of stroke onset was still as safe as within
3 hours, although no statistical benefit could be
confirmed as compared with a placebo (3). The au-
thors of the latter study concluded that the higher
dose of rTPA may have contributed to better effi-
cacy, and that individual characteristics, such as the
site and extent of thrombus and collateral blood
flow, may be relevant. However, ECASS I dem-
onstrated that intravenous rTPA at higher doses
leads to a higher mortality rate (2).
Intraarterial administration of rTPA helps to
achieve a high concentration of the thrombolytic
drug in the affected vascular territory without an
excessive systemic dose rate. It has been reported
that LIT with rTPA at doses of 20 to 40 mg is safe
and effective within 6 hours of stroke onset and
even beyond (4, 5, 8). In addition, angiography per-
formed before LIT depicts vascular disorders and
provides information on collateral flow.
In the present study, we decided to begin LIT
treatment with the minimum dose required for ther-
apeutic workup. The plasma half-life of rTPA is
reported to be 5 minutes, but its biological activity,
once bound to a clot, may last for several hours
(23). Therefore, for the best efficacy, rTPA should
be administrated as a continuous infusion after an
initial bolus (24), which is why we combined LIT
with a follow-up intravenous infusion of rTPA.
Although angiography itself very early in the
course of cerebral ischemia is reported to be fea-
sible and safe (13), the risk of complications in-
creases with intraarterial selective catheterization
and administration of a contrast agent (25). Such
an increased risk may be acceptable on behalf of
the state of the art, as in the one randomized, con-
trolled, double-blind trial of LIT (26) and as needed
to reach a high level of significance; however, the
absence of a placebo was one reason why angiog-
raphy was not included in our protocol for the con-
trol group.
Coadministration of rTPA and heparin appears
to produce a contradictory effect. According to the
recommendations of the American Heart Associa-
tion (10), persons given intravenous rTPA in clin-
ical practice should not receive antithrombotic or
antiplatelet drugs within 24 hours of treatment
(however, it was also stated that additional research
on the usefulness of such adjunctive therapies is
needed, because they may affect the time to lysis,
degree of reperfusion, occurrence of reocclusion,
and/or clinical outcome). In contrast, it has been
shown that rTPA at a dose of 100 mg can be given
intravenously together with heparin (5000 U bolus
followed by 1000 U/h) with acceptable safety (9,
14). Indeed, subcutaneous heparin (not exceeding
10,000 U) was allowed during the first 24 hours in
ECASS I and ECASS II for prophylaxis of deep-
vein thrombosis (2, 3).
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Intraarterial manipulation to reopen an occluded
artery is usually performed just after intravenous
administration of a 5000-U bolus of heparin (4, 27,
28); in the prolyse in acute cerebral thromboem-
bolism trial, both groups received intravenous hep-
arin (26). Therefore, in the present study, 5000 U
of heparin after the first CT study, followed by
5000 U subcutaneously twice daily, produced a re-
sponse to a modest coadministration of heparin for
maintenance of intraarterial catheters and as anoth-
er prophylaxis of thrombosis. Furthermore, recent
findings in a clinical investigation suggest that hep-
arin may play a role as an adjunctive treatment in
the thrombolysis of stroke (29), as it does in myo-
cardial infarction (30). Moreover, in another study,
rTPA treatment for acute stroke was characterized
by a massive and sustained increase in activation
markers of coagulation (31), a finding that supports
adjunctive anticoagulation for ischemic stroke
treated with rTPA.
Our clinical research was intended to be a pilot
study in which both with the thrombolysis and con-
trol groups received the best available therapy.
However, our results failed to demonstrate a clear
benefit for the therapeutic method because of the
baseline differences between the groups (Table 1),
which weakened the comparison and moved the
study toward the format of a case series. On the
other hand, the following discussion of the results
may encourage further attempts to improve the ef-
ficacy of thrombolysis for patients with acute is-
chemic stroke.
The overall distribution of good outcome (MRS
score, 0–3) at 1 month and at 12 months in the
groups (thrombolysis/control) were 67%/21% and
83%/33%, respectively. A post hoc analysis of
MRS scores in the ECASS II trial dichotomized for
dependency (scores of 0, 1, and 2 were classified
as favorable) revealed that 54% of patients in the
rTPA group and 46% in the placebo group were
independent at day 90. In the NINDS study, 61%
of patients in the rTPA group and 51% in the pla-
cebo group had an MRS score of 0 to 3 at 3
months. Recent studies with LIT found an overall
good outcome (defined as MRS scores of 0–3) at
3 months in 61% of patients (7) and at 6 months
in 65% of patients (32). The good outcome at 1
month in our study is consistent with those reported
before (1, 7). A notable absolute difference that
might favor rTPA treatment may be the location of
thrombus: in patients with MCA occlusions, out-
come after LIT compared with a natural course
showed a 30% increase in the number of patients
with minimal or no disability (6).
Despite the relatively low dose of rTPA, hem-
orrhagic conversion was almost three times more
common in the thrombolysis group than in the con-
trol group (17% versus 6%). However, this differ-
ence did not lead to increased mortality and there
were no symptomatic intracerebral hemorrhages in
the thrombolysis group. During the first 30 days,
more deaths occurred in the control group relative
to the thrombolysis group (48% versus 17%), and
this difference was even more obvious at 12
months (64% versus 17%). After intravenous ad-
ministration of rTPA within 6 hours of stroke onset,
parenchymal hemorrhage was roughly four times
more common in the rTPA group (12% versus 3%)
in the ECASS II trial and similarly (9% versus 2%)
within 3 hours in the NINDS study; there were no
significant differences in mortality at 3 months be-
tween the rTPA and control groups in the ECASS
II trial (10.5% versus 10.7%) or in the NINDS
study (17% versus 21%) (1, 3). In a community-
based approach (29), the rates of intracerebral hem-
orrhage and mortality after early (within 3 hours of
onset) intravenous thrombolysis for acute ischemic
stroke were reported to be 11% and 12%, respec-
tively. After intravenous administration of rTPA
within 1 hour 30 minutes (22) and within 8 hours
(13) of stroke onset, the overall rates of hemor-
rhagic conversion/death at 30 days were 4%/8%
and 31%/13%, respectively. Although the time to
thrombolysis should be considered an important
predictor of outcome and adverse events, a time-
related association between hemorrhagic conver-
sion and mortality after intravenous administration
of rTPA within the reported hours and doses is not
strong.
LIT in the carotid territory using rTPA with a
mean time delay from 4 hours 40 minutes to 6
hours 30 minutes (in different subgroups) was re-
ported to be associated with 18 cases (13%) of
hemorrhage (one symptomatic) and seven deaths
(5%) in a series of 142 patients (5); in no patient
did secondary hemorrhagic transformation (six cas-
es, 18%) cause clinical deterioration, and eight pa-
tients (24%) died after LIT for a carotid territory
stroke within 6 hours of onset (4). However, if an
occlusion of the ICA bifurcation was treated with
intraarterial rTPA, reported mortality ranged from
53% to 62% (8, 9).
The rates of adverse events and mortality ob-
served after combined intraarterial/intravenous
thrombolysis may be estimated according to re-
ported results of intravenous thrombolysis and LIT.
The rates of hemorrhagic conversion in both study
groups may be acceptable and consistent with the
experience discussed above (1, 3, 4, 29). Converse-
ly, the rates of poor outcome and mortality in the
control group were considerably higher relative to
those in the control groups in related studies. Sev-
eral reasons could account for this difference. First,
a remarkable difference between mean ages in the
groups was suspected. Nevertheless, the post hoc
analysis of age in the control group revealed that
mean ages in the outcome subgroups (good, poor-
disabled, and poor-dead) were similar. Second, the
percentage of left-sided strokes in which cognition
was impaired was tested because of the possible
impact on quality of outcome in survivors. Again,
there were more strokes in the left ICA territory in
the good subgroup than in the poor-disabled sub-
group (57% versus 50%). Clinical history may be
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another factor in the different outcomes in the
groups, as suggested by the natural course of pa-
tients with a stable and severe ischemic hemispher-
ic syndrome of sudden onset. Usually caused by
carotid T occlusion, M1 occlusion, or distal MCA
occlusion, this syndrome is associated with high
rates of major morbidity, with mortality rates as
high as 55% in some series (6, 8, 9), and in patients
with massive strokes, mortality may be as high as
70% to 100% at 3 months (33).
The primary goal of thrombolysis in stroke pa-
tients should be the rapid restoration of blood sup-
ply. However, data evaluating the efficacy of
thrombolysis based only on the revascularization
rate of occluded arteries are not sufficiently accu-
rate, because an artery can be reopened yet not ef-
ficient (4, 5, 8). Conversely, a good clinical out-
come may be obtained even when an artery
remains occluded, because of thrombolysed collat-
erals (5, 34, 35). Our study confirmed the rapid
reopening of an occluded artery as a predictor of
outcome in 67% of patients: in five patients recan-
alization (one partial) resulted in a good outcome
and in three patients nonrecanalization resulted in
a poor outcome. Results in the remaining 33% of
patients supported the opinion that findings on a
control angiogram after thrombolysis could be elu-
sive in regard to outcome. Another pilot study
showed that combined intraarterial/intravenous
thrombolysis is feasible and provides better recan-
alization, although it was not associated with im-
proved clinical outcome (36).
The foregoing may allow us to expect that the
workup for intraarterial administration of rTPA,
recognized at present as a limitation of LIT, could
be reduced to a minimum, consisting of an intra-
arterial injection under fluoroscopic guidance.
However, patients with a T-type occlusion of the
ICA may experience little potential benefit from
thrombolysis (4, 7, 9, 37, 38) and may be excluded
on the basis of findings at sonography, CT angi-
ography, or MR angiography (22, 38–40).
Conclusion
The present study indicates that combined intra-
arterial/intravenous thrombolysis with low-dose
rTPA may be a safe and effective treatment for
acute ischemic stroke if administered within 6
hours of onset in carefully selected patients. How-
ever, because of the differences in baseline char-
acteristics between our groups and the small num-
ber of cases, further research is needed to assess
the significance of this observation.
References
1. The National Institute of Neurological Disorders and Stroke rt-PA
Stroke Study Group. Tissue plasminogen activator for acute is-
chemic stroke. N Engl J Med 1995;333:1581–1587
2. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis
with recombinant tissue plasminogen activator for acute hemi-
spheric stroke: the European Cooperative Acute Stroke Study
(ECASS). JAMA 1995;274:1017–1025
3. Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind
placebo-controlled trial of thrombolytic therapy with intra-
venous alteplase in acute ischaemic stroke (ECASS II). Lancet
1998;352:1245–1251
4. Zeumer H, Freitag H-J, Zanella F, Thie A, Arning C. Local intra-
arterial fibrinolytic therapy in patients with stroke: urokinase
versus recombinant tissue plasminogen activator (r-TPA).
Neuroradiology 1993;35:159–162
5. Theron J, Coskun O, Huet H, Oliveira G, Toulas P, Payelle G.
Local intraarterial thrombolysis in the carotid territory. Inter-
vent Neuroradiol 1996;2:111–126
6. Bendszus M, Urbach H, Ries F, Solymosi L. Outcome after local
intra-arterial fibrinolysis compared with the natural course of
patients with a dense middle cerebral artery on early CT. Neu-
roradiology 1998;40:54–58
7. Gonner F, Remonda L, Mattle H, et al. Local intra-arterial
thrombolysis in acute ischemic stroke. Stroke 1998;29:1894–
1900
8. Endo S, Kuwayama N, Hirashima Y, Akai T, Nishijima M, Takaku
A. Results of urgent thrombolysis in patents with major stroke
and atherothrombotic occlusion of the cervical internal carotid
artery. AJNR Am J Neuroradiol 1998;19:1169–1175
9. Jensen O, von Kummer R, Forsting M, Hacke W, Sartor K.
Thrombolytic therapy in acute occlusion of the intracranial
internal carotid artery bifurcation. AJNR Am J Neuroradiol
1995;16:1977–1986
10. American Heart Association. Guidelines for thrombolytic ther-
apy for acute stroke: a supplement to the guidelines for the
management of patients with acute ischemic stroke: a state-
ment for healthcare professionals from a special writing group
of the Stroke Council, American Heart Association. Circulation
1996;4:1167–1174
11. Haley EC Jr, Brott TG, Sheppard GL, et al. Pilot randomized
trial of tissue plasminogen activator in acute ischemic stroke.
Stroke 1993;24:1000–1004
12. Brott TG, Adams HP, Olinger CP, et al. Measurement of acute
cerebral infarction: a clinical examination scale. Stroke 1989;
20:864–870
13. del Zoppo GJ, Poeck K, Pessin MS, et al. Recombinant tissue
plasminogen activator in acute thrombotic and embolic stroke.
Ann Neurol 1992;32:78–86
14. von Kummer R, Hacke W. Safety and efficacy of intravenous
tissue plasminogen activator and heparin in acute middle ce-
rebral artery stroke. Stroke 1992;22:646–652
15. Chesebro JH, Knatterud G, Roberts R, et al. Thrombolysis in
myocardial infarction (TIMI) trial, phase I: a comparison be-
tween intravenous tissue plasminogen activator and intrave-
nous streptokinase: clinical findings through hospital dis-
charge. Circulation 1987;76:142–154
16. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJA, van
Gijn J. Inter-observer agreement for the assessment of handi-
cap in stroke patients. Stroke 1988;19:604–607
17. Sussmann BJ, Fitch TSP. Thrombolysis with fibrinolysis in ce-
rebral artery occlusion. JAMA 1958;167:1705–1709
18. Donnan GA, Davis SM, Chambers BR, et al. Trials of streptoki-
nase in severe acute ischemic stroke. Lancet 1995;345:578–579
19. Multicentre Acute Stroke Trial-Italy (MAST-I) Group. Random-
ised controlled trial of streptokinase, aspirin, and combination
of both in treatment of acute ischemic stroke. Lancet 1995;346:
1509–1514
20. Multicenter Acute Stroke Trial-Europe Study Group. Thrombo-
lytic therapy with streptokinase in acute ischemic stroke. N
Engl J Med 1996;335:145–150
21. Fisher M, Bogousslavsky J. Further evolution toward effective
therapy for acute ischemic stroke. JAMA 1998;279:1298–1303
22. Brott TG, Haley EC Jr, Levy DE, et al. Urgent therapy for
stroke, part I: pilot study of tissue plasminogen activator ad-
ministrated within 90 minutes. Stroke 1992;23:632–640
23. Eisenberg PR, Sherman LA, Tiefenbrunn AJ, Ludbrook PA, Sobel
BE, Jaffe AS. Sustained fibrinolysis after administration of t-
PA despite its short half-life in the circulation. Thromb Hae-
most 1987;57:35–40
24. Silver B, Weber J, Fisher M. Medical therapy for ischemic
stroke: review. Clin Neuropharmacol 1996;19:101–128
25. Culebras A, Kase CS, Masedu JC, et al. Practice guidelines for
the use of imaging in transient ischemic attacks and acute
stroke: a report of Stroke Council, American Heart Associa-
tion. Stroke 1997;28:1480–1497
AJNR: 22, February 2001358 KERIS
26. del Zoppo GJ, Higashida RT, Furlan AJ, et al. The prolyse in
acute cerebral thromboembolism trial (PROACT): results of
6 mg dose tier. Stroke 1996;27:164
27. Nakano S, Yokogami K, Ohta H, Yano T, Ohnishi T. Direct per-
cutaneous transluminal angioplasty for acute middle cerebral
artery occlusion. AJNR Am J Neuroradiol 1998;19:767–772
28. Levy DI. Endovascular treatment of carotid artery occlusion
in progressive stroke syndromes: technical note. Neurosurgery
1998;42:186–193
29. Grond M, Stenzel C, Schmulling S, et al. Early intravenous
thrombolysis for acute ischemic stroke in a community-based
approach. Stroke 1998;29:1544–1549
30. Gunnar RM, Passamani ER, Bourdillon PDV, et al. Guidelines
for the early management of patients with acute myocardial
infarction: a report of the American College of Cardiology/
American Heart Association task force on assessment of di-
agnostic and therapeutic cardiovascular procedures. J Am Coll
Cardiol 1990;16:249–292
31. Fassbender K, Dempfle CE, Mielke O, et al. Changes in coagu-
lation and fibrinolysis markers in acute ischemic stroke treat-
ed with recombinant tissue plasminogen activator. Stroke 1999;
30:2101–2104
32. Ueda T, Sakaki S, Kumon Y, Ohta S. Multivariable analysis of
predictive factors related to outcome at 6 months after intra-
arterial thrombolysis for acute ischemic stroke. Stroke 1999;
30:2360–2365
33. Clark WM, Albers GW, Madden KP, Hamilton S, for the Throm-
bolytic Therapy in Acute Ischemic Stroke Study Investigators.
The rtPA (Alteplase) 0- to 6-hour acute stroke trial, part A
(A0276g). Stroke 2000;31:811–816
34. Herderschee D, Limburg M, van Royen EA, Hijdra A, Buller HR,
Koster PA. Thrombolysis with recombinant tissue plasminogen
activator in acute ischemic stroke: evaluation with rCBF-
SPECT. Acta Neurol Scand 1991;83:317–322
35. Grotta JC, Alexandrov AV. tPA-associated reperfusion after
acute stroke demonstrated by SPECT. Stroke 1998;29:429–432
36. Lewandowski CA, Frankel M, Tomsick TA, et al. Combined in-
travenous and intra-arterial r-TPA versus intra-arterial ther-
apy of acute ischemic stroke. Stroke 1999;30:2598–2605
37. Kucinski T, Koch C, Grzyska U, Freitag H-J, Kromer H, Zeumer
H. The predictive value of early CT and angiography for fatal
hemispheric swelling in acute stroke. AJNR Am J Neuroradiol
1998;19:839–846
38. Wildermuth S, Knauth M, Brandt T, Winter R, Sartor K, Hacke W.
Role of CT angiography in patient selection for thrombolytic
therapy in acute hemispheric stroke. Stroke 1998;29:935–938
39. Kaps M, Link A. Transcranial sonographic monitoring during
thrombolytic therapy. AJNR Am J Neuroradiol 1998;19:758–760
40. Gillard JH, Oliverio PJ, Barker PB, Oppenheimer SM, Bryan RN.
MR angiography in acute cerebral ischemia of the anterior
circulation: a preliminary report. AJNR Am J Neuroradiol
1997;18:343–350
